Radio Astronomy driving new competences and innovation on the European scale

LOFAR (Low Frequency Array) is the world’s largest and most sensitive low frequency radio telescope. It was designed, built, and is now operated by ASTRON, the Netherlands Institute for Radio Astronomy. LOFAR’s reach now spans Europe – from Ireland to Poland, with the newest LOFAR antenna station being delivered to Ventspils University of Applied Sciences in Latvia. Here we propose that LOFAR is a prime example of how state-of-the-art facilities leads to the sharing and building of competencies and innovation: it is one of today’s major success stories of research infrastructures on a European scale.

Conflicting values of biomedical innovation?

The term ‘value’ is at the centre of an increasingly explicit debate in the fields of health and healthcare policy. ‘Value’ is understood in many different ways and diverging interests are being mobilised. How are values in biomedical innovation being expressed, represented, materialised and aligned or contested in different areas of biomedicine? How do values embedded in regulation, public health, economic policies, healthcare provision, technology assessment, producers’ strategies, and patient organisation movements shape biomedical innovations? At an ESOF discussion in Toulouse multidisciplinary perspectives on value between panel members and public participants will be explored and possible pathways to common solutions identified that promote socially acceptable biomedical innovation in the European context.

Webinar: “Responsible Research and Innovation: a check-up”

Responsible Research and Innovation (RRI) has become a buzzword in European science in the last few years. Scientists must fill in the RRI section in their European project and sometimes they don’t know what to write there. Others are anxious to have the RRI tag attached to their communication and PR activities. But what RRI really is? Why is it needed? How could science and society benefit from this approach? The strict definition of RRI implies a radical change in the way of conceiving scientific projects from the very beginning, bringing a wide range of stakeholders (from companies to activists, from designers to patients…) in defining the scientific agenda. Are researchers prepared for that? What is the actual level of implementation of RRI in European science? What policies are there in place to facilitate this process?